Canada markets open in 4 hours 32 minutes

Pharmala Biotech Holdings Inc. (MDMA.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.1750+0.0100 (+6.06%)
At close: 03:44PM EDT
Full screen
Previous Close0.1650
Open0.0000
Bid0.1750 x N/A
Ask0.1800 x N/A
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume673,216
Market Cap14.871M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0100
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office

    Novel Composition of MDMA Enantiomers leading to next-generation MDMA possibilitiesTORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is extremely pleased to announce that the US Patent and Trademark Office (USPTO) has indicated it is issuing an allowance for the granting

  • GlobeNewswire

    PharmAla Biotech Signs Sale Agreement with Numinus

    LaNeo Product Data submitted for a Clinical Trial in CanadaTORONTO, March 26, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA, OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it had entered into a binding sales agreement with Numinus Wellness Inc. (“Numinus”) (TSX: NUMI, OTCQX: NUMIF) to provide its GMP LaNeo

  • GlobeNewswire

    Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office

    Novel MDMA-Like Drug Could Be Used for Numerous Neurological and Psychiatric Indications P-1 molecular structure P-1 molecular structure TORONTO, March 20, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is thrilled to announce that allowance has been granted for the Composition of Matte